John joined Vicarious Surgical in March of 2022 as SVP of Operations and has over 35 years of medical device industry experience.
He has been involved with over 25 medical device product launches encompassing both Class II and Class III devices.
Prior to joining the Vicarious Surgical team, he spent 13 years in senior executive roles and product development leadership positions, including serving as VP of Operations at Becton Dickinson Surgery overseeing a network of 10 manufacturing sites, a business planning and procurement organization, an advanced manufacturing engineering team, and the business' environmental health and safety responsibilities.
In the past year, John has led strategic manufacturing plans for the Vicarious Surgical robotic system, overseeing operations and quality organizations.
In the newly created chief operating officer role, John's oversight expands to include the Product Development, Clinical & Regulatory Affairs, IT and People & Culture functions of the business for enhanced workflow efficiency and a continued focus on manufacturing and procurement optimization.
Founded in 2014, Vicarious Surgical is a next generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs.
The company's novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery.
The company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, Innovation Endeavors, Jerry Yang's AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang's E15 VC.
The company is headquartered in Waltham, Massachusetts.
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study
Nicox and Glaukos sign exclusive research and licensing option agreement
Creo Medical forms strategic partnership with Micro-Tech via EUR36.7m subsidiary sale
Epitomee Medical's Capsule cleared by FDA for weight management
Eurofins strengthens biopharma testing in US with Infinity Labs acquisition